Xylazine is an important animal sedative used to facilitate the safe handling and treatment of many species. Recently, illicit xylazine is increasingly showing up in street drugs as traffickers have begun mixing xylazine with fentanyl and other narcotics. Collaborative efforts among congressional offices, the AVMA, stakeholders, and federal agencies to address the complexities of the xylazine issue led to the introduction of the Combating Illicit Xylazine Act (H.R. 1839/S. 993) – an AVMA-supported, bipartisan bill that would provide harsher penalties for trafficking illicit xylazine while maintaining current veterinary access to this important animal sedative. Please join the veterinary community and urge your members of Congress to support the Combating Illicit Xylazine Act through the AVMA’s Congressional Advocacy Network.